The acute respiratory distress syndrome market is expected to grow, driven by factors such as an increase in the incident pool, expected entry of emerging therapies such as MultiStem (HLCM051) ...
Inhaled sevoflurane significantly reduced ventilator-free days and 90-day survival versus IV propofol in moderate to severe ARDS. Inhaled volatile sedatives grew in popularity for prolonged use in ...
HONOLULU — Patients with acute respiratory distress syndrome (ARDS) and coexisting pulmonary hypertension (PH) are significantly more likely to have longer and more costly hospital stays and to die in ...
Please provide your email address to receive an email when new articles are posted on . Pulmonary hypertension plus acute respiratory distress syndrome resulted in poor hospital outcomes. Odds for ...
Please provide your email address to receive an email when new articles are posted on . Researchers have identified two new distinct subphenotypes of adults with acute respiratory distress syndrome, ...
A team of international scientists have recently estimated the risk and prevalence of acute respiratory distress syndrome (ARDS) in hospitalized young adults with severe acute respiratory syndrome ...
Promising trial results indicate that a new type of cell therapy could improve the prognosis of those who are critically ill with acute respiratory distress syndrome (ARDS) resulting from severe COVID ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results